Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) received approval from China's National Medical Products Administration for the clinical trials of SHR-1049 injection, according to a Tuesday filing on the Shanghai bourse.
The pharmaceutical company invested 26 million yuan into the research and development of the drug, which is used for the treatment of advanced solid tumors.
The company's shares fell less than 2% during the midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.